{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:13Z","timestamp":1793390713222,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["No. 2022YFC3501301\uff1b2022YFC3501305"],"award-info":[{"award-number":["No. 2022YFC3501301\uff1b2022YFC3501305"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82205107"],"award-info":[{"award-number":["No. 82205107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Development Plan Project of Jilin Province, China","award":["No. 20210101212JC"],"award-info":[{"award-number":["No. 20210101212JC"]}]},{"name":"the Youth discipline backbone training project of Changchun university of Chinese Medicine","award":["202310"],"award-info":[{"award-number":["202310"]}]},{"name":"the Yong Elite Scientists Sponsorship Program by CACM","award":["2022-QNRC2-A08"],"award-info":[{"award-number":["2022-QNRC2-A08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02859-3","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:21:00Z","timestamp":1746782460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials"],"prefix":"10.1186","volume":"14","author":[{"given":"Chang","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xikang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-7305","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-1323","authenticated-orcid":false,"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"3","key":"2859_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"8","key":"2859_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"5","key":"2859_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","volume":"34","author":"S Alabbad","year":"2020","unstructured":"Alabbad S, AlGaeed M, Sikorski P, et al. Monoclonal antibody-based therapies for myasthenia gravis. BioDrugs. 2020;34(5):557\u201366.","journal-title":"BioDrugs"},{"issue":"04","key":"2859_CR4","first-page":"21","volume":"22","author":"J Li","year":"2024","unstructured":"Li J, Chen Y, Cao W, et al. Efgartigimod alpha, a neonatal Fc receptor antagonist for the treatment of generalised myasthenia gravis. J Clin Pharmacother. 2024;22(04):21\u20135.","journal-title":"J Clin Pharmacother"},{"issue":"10","key":"2859_CR5","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J Clin Invest"},{"key":"2859_CR6","doi-asserted-by":"publisher","first-page":"1280218949","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1280218949.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"2859_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364.","journal-title":"Drugs"},{"issue":"2","key":"2859_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MN, Waheed W, et al. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185\u201396.","journal-title":"Muscle Nerve"},{"issue":"2","key":"2859_CR9","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1002\/mus.26152","volume":"58","author":"J Vissing","year":"2018","unstructured":"Vissing J, O\u2019Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study. Muscle Nerve. 2018;58(2):E21\u20132.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2859_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mus.25002","volume":"54","author":"VR Ostovan","year":"2016","unstructured":"Ostovan VR, Fatehi F, Davoudi F, et al. Validation of the 15-item myasthenia gravis quality of life questionnaire (MG-QOL15) Persian version. Muscle Nerve. 2016;54(1):65\u201370.","journal-title":"Muscle Nerve"},{"key":"2859_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","volume":"2345","author":"J Watt","year":"2022","unstructured":"Watt J, Del GC. Network meta-analysis. Methods Mol Biol. 2022;2345:187\u2013201.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2859_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11(2):815\u201334.","journal-title":"Neurol Ther"},{"issue":"4","key":"2859_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y, et al. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2024;81(4):336\u201345.","journal-title":"JAMA Neurol"},{"issue":"23","key":"2859_CR14","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JJ Howard","year":"2019","unstructured":"Howard JJ, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"issue":"7","key":"2859_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JJ Howard","year":"2021","unstructured":"Howard JJ, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2859_CR16","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"issue":"12","key":"2859_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JJ Howard","year":"2017","unstructured":"Howard JJ, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2859_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JJ Howard","year":"2020","unstructured":"Howard JJ, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582\u201392.","journal-title":"JAMA Neurol"},{"issue":"5","key":"2859_CR19","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"16","key":"2859_CR20","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","journal-title":"Neurology"},{"issue":"11","key":"2859_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105\u201312.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2859_CR22","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376\u201389.","journal-title":"Neurology"},{"key":"2859_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1229112","volume":"14","author":"V Bhandari","year":"2023","unstructured":"Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023;14: 1229112.","journal-title":"Front Neurol"},{"issue":"1","key":"2859_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000536","volume":"6","author":"M Benatar","year":"2024","unstructured":"Benatar M, Wiendl H, Nowak R, et al. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol Open. 2024;6(1): e536.","journal-title":"BMJ Neurol Open"},{"issue":"5","key":"2859_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","volume":"36","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. Curr Opin Neurol. 2023;36(5):410\u20135.","journal-title":"Curr Opin Neurol"},{"issue":"871","key":"2859_CR26","first-page":"848","volume":"20","author":"E Sukockien\u00e9","year":"2024","unstructured":"Sukockien\u00e9 E, Th\u00e9audin M, Loser V, et al. [Novel immunomodulatory therapies in myasthenia gravis]. Rev Med Suisse. 2024;20(871):848\u201351.","journal-title":"Rev Med Suisse"},{"issue":"2","key":"2859_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113\u201324.","journal-title":"Nat Rev Neurol"},{"key":"2859_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","volume":"40","author":"D Ramsk\u00f6ld","year":"2019","unstructured":"Ramsk\u00f6ld D, Parodis I, Lakshmikanth T, et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019;40:517\u201327.","journal-title":"EBioMedicine"},{"issue":"7","key":"2859_CR29","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328\u201337.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2859_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1756-185x.12002","volume":"16","author":"PK Chugh","year":"2013","unstructured":"Chugh PK, Kalra BS. Belimumab: targeted therapy for lupus. Int J Rheum Dis. 2013;16(1):4\u201313.","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"2859_CR31","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, et al. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02859-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:21:01Z","timestamp":1746782461000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2859"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02859-3","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}